Dear members,
I thank you for answering my question in the most helpful way.
Here a brief summary of indications received:
- ASERNIP-S: www.racs.edu.au/open/asernip-s.htm (go to the publications
page).
- The Technology Evaluation Center, Blue Cross Blue Shield Association,
technology assessment of TUMT-Prostatron in BPH. [log in to unmask]
- The American Urological Association is currently revising its guidelines
on
BPH.
- The University Healthsystem Consortium, in the U.S.: Benign Prostatic
Hyperplasia Treatments Technology Assessment. (1995) No. TA1023
http://www.uhc.edu/
- The British Columbia Office of Health Technology Assessment: BCOHTA
1996:1D Bassett K, Kazanjian A.
Incorporating Clinical Effectiveness Debates Into Hospital Technology
Assessment: the Case of Laser Treatment of Benign Prostatic Hyperplasia.
http://www.chspr.ubc.ca//bcohta/pdf/laser.pdf
See also: UK Centre for Reviews & Dissemination databases (especially the
HTA database).http://agatha.york.ac.uk/welcome.htm: interesting citation at
CRD database:
a) The economic impact of introducing transurethral microwave
thermotherapy in the treatment of benign
prostatic hyperplasia - a scenario analysis
Baltussen R M P M, Wielink G, Stoevelaar H J, Van der Wilt G J,
Severens J L, Ament A J H A. World Journal of
Urology,, 1998, 16(2),, 142-147
b) Economics of transurethral thermotherapy of the prostate
c) Benign prostatic hyperplasia.
NHS Centre for Reviews and Dissemination York: NHS Centre for
Reviews and Dissemination, 1995. pp.16
Kind regards
dr. Federico Barbani
Health Purchasing Service
AUSL Modena - Local Health Unit
Italy
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|